title: Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors.
abstract: Dendritic cell (DC) precursors and immature DC reside in epithelium where they encounter pathogens and cytokines, which stimulate their differentiation. We hypothesized that type-I interferons (IFN-alpha and -beta), cytokines that are produced early in the innate immune response against viruses and some bacteria, may influence DC differentiation and function. To examine this possibility, we used an in vitro model of DC differentiation in which initial culture of human CD14(+) monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 generates immature DC, and subsequent culture with tumor necrosis factor (TNF)-alpha drives the final development into mature DC. We found in this model that IFN-alpha/beta, added from the initiation of the culture on, significantly reduced the survival and altered the morphology and differentiation of DC. TNF-alpha-dependent maturation of IFN-beta-treated immature DC led to cells with reduced expression of CD1a, CD40, CD54, and CD80 when compared with mature DC controls. IFN-alpha/beta-treated DC further had a reduced capacity to induce naive Th-cell proliferation through allostimulation or anti-CD3 monoclonal antibody stimulation. In addition, IFN-alpha/beta-treated DC secreted less IL-12 upon stimulation with Staphylococcus aureus Cowan strain or with CD4(+) T cells, and this decrease correlated directly with their inability to support CD4(+) T-cell secretion of IFN-gamma, even though T-cell lymphotoxin production was unaffected. These findings indicate that type-I IFNs can influence the generation of acquired immune responses by modifying T-helper cell differentiation through the regulation of DC differentiation and function.
authors.affiliation: Committee on Immunology, Department of Pathology, Division of Biological Science, University of Chicago, Chicago, IL 60637, USA.
authors.forename: B L
authors.initials: BL
authors.lastname: McRae
authors.forename: T
authors.initials: T
authors.lastname: Nagai
authors.forename: R T
authors.initials: RT
authors.lastname: Semnani
authors.forename: J M
authors.initials: JM
authors.lastname: van Seventer
authors.forename: G A
authors.initials: GA
authors.lastname: van Seventer
mesh_terms: D015703:Antigens, CD / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007121:Immunocompetence; D007370:Interferon Type I / Q000494:pharmacology*; D016898:Interferon-alpha / Q000494:pharmacology*; D007376:Interleukin-2 / Q000096:biosynthesis; D007700:Kinetics; D018950:Lipopolysaccharide Receptors / Q000097:blood*; D008213:Lymphocyte Activation; D009000:Monocytes / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D011994:Recombinant Proteins
chemical_list: D015703:Antigens, CD; D007370:Interferon Type I; D016898:Interferon-alpha; D007376:Interleukin-2; D018950:Lipopolysaccharide Receptors; D011994:Recombinant Proteins